Home / Market News / $AVBP

$AVBP news and market catalysts

The 3 most recent market catalysts affecting $AVBP, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

3 catalysts 1 high impact 1 bullish 1 bearish Biotechnology

Aug 17, 2026 Corporate Catalyst Bullish Impact 55

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $47

HC Wainwright & Co. analyst Robert Burns has maintained a 'Buy' rating on ArriVent BioPharma (AVBP) and raised the price target from $44 to $47. This action signals continued analy…

Aug 13, 2026 Corporate Catalyst Neutral Impact 55

Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price Target

Guggenheim analyst Michael Schmitz has reaffirmed a 'Buy' rating and a $45 price target for ArriVent BioPharma. This action signals that the analyst's positive outlook on the compa…

Aug 12, 2026 Corporate Catalyst Bearish Impact 92

ArriVent BioPharma Q2 EPS $(1.05) Misses $(0.99) Estimate

ArriVent BioPharma (AVBP) reported a Q2 EPS of $(1.05), missing the consensus estimate of $(0.99) and representing a 16.67% increase in losses year-over-year. This earnings miss is…

Join the waitlist for full signal validation →

New to reading filings? What an SEC 8-K is and why it moves prices

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.